The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world clinical outcomes in a U.S. Asian population with stage IV NSCLC treated with osimertinib (Osi) stratified by EGFR subtype.
 
Ying Liu
No Relationships to Disclose
 
Jason Bi
No Relationships to Disclose
 
Andre Moreira
Research Funding - BMS GmbH & Co. KG
 
Abraham Chachoua
No Relationships to Disclose
 
Vamsidhar Velcheti
Honoraria - ITeos Therapeutics
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Elevation Oncology; GlaxoSmithKline; Merck; Merus; Taiho Oncology
Research Funding - Alkermes (Inst); Altor BioScience (Inst); Atreca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech (Inst); Genoptix (Inst); GlaxoSmithKline (Inst); Heat Biologics (Inst); Leap Therapeutics (Inst); Merck (Inst); NantWorks (Inst); OncoPlex Diagnostics (Inst); RSIP Vision (Inst); Trovagene (Inst)
 
Sally C. M. Lau
No Relationships to Disclose
 
Salman Rafi Punekar
Research Funding - Astellas Pharma (Inst); Constellation Pharmaceuticals (Inst); NCI (Inst); Prelude Therapeutics (Inst); Revolution Medicines (Inst); Simcere (Inst); Tango Therapeutics (Inst); VITRAC Therapeutics (Inst)
 
Joshua K. Sabari
Consulting or Advisory Role - AstraZeneca; Janssen Oncology; Medscape; Navire; Pfizer; Regeneron; Takeda
 
Elaine Shum
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Genentech; Janssen
Research Funding - Delfi Diagnostics (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Nektar